{
  "first_published_at": "2013-11-14", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336716", 
  "title": "Antiepileptic drugs: new advice on switching between different manufacturersâ€™ products for a particular drug", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\"]}", 
  "_document_number": 52, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "neurology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Antiepileptic drugs: new advice on switching between different manufacturers&#8217; products for a particular drug</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Different antiepileptic drugs (AEDs) vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers&#8217; products of a particular drug may cause adverse effects or loss of seizure control. AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer&#8217;s product</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Bioequivalence and antiepileptic drugs</strong></p>\n\n<p>When a generic medicinal product is shown to be bioequivalent to the originator (reference) product, as defined by the relevant regulations and guidelines, it follows that the products can be considered to be clinically equivalent. However, concerns about switching between different manufacturers&#8217; products of an oral antiepileptic drug (AED) have been raised by patients and prescribers. These include switching between branded originator and generic products, and between different generic products of a particular drug. The main reasons for these concerns are the narrow therapeutic index of some AEDs and the potentially serious consequences of therapeutic failure. Drug&#8211;drug interactions and the relatively low solubility or bioavailability (or both) of some AEDs are other important factors.</p>\n\n<p><strong>Potential risk from switching between different manufacturers&#8217; products</strong></p>\n\n<p>The Commission on Human Medicines (CHM) reviewed spontaneous adverse reactions received by MHRA and publications that reported potential harm arising from switching of AEDs in patients previously stabilised on a branded product to a generic. Following this review, CHM concluded that reports of loss of seizure control and/or worsening of side effects around the time of switching between products could be explained as chance associations, but that a causal role of switching could not be ruled out in all cases.</p>\n\n<p><strong>New categorisation to help minimise risk</strong></p>\n\n<p>The CHM considered the characteristics of AEDs and advised that they could be classified into three categories based on therapeutic index, solubility, and absorption to help prescribers and patients decide whether it was necessary to maintain continuity of supply of a specific manufacturer&#8217;s product. These categories are listed below:</p>\n\n<div class=\"websitebluehighlightbox70\">\n<ul>\n<li><strong>Category 1 &#8211; </strong>phenytoin, carbamazepine, phenobarbital, primidone</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer&#8217;s product</p>\n</li>\n\n<li><strong>Category 2 &#8211; </strong>valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, the need for continued supply of a particular manufacturer&#8217;s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history</p>\n</li>\n\n<li><strong>Category 3 - </strong>levetiracetam, lacosamide, tiagabine, gabapentin, pregabalin, ethosuximide, vigabatrin<strong> </strong>&#160;</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer&#8217;s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors</p>\n</li>\n</ul>\n</div>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for prescribers:</strong></p>\n\n<ul>\n<li>Different AEDs vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers&#8217; products of a particular drug may cause adverse effects or loss of seizure control</li>\n\n<li>AEDs have been divided into three categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer&#8217;s product</li>\n\n<li>If it is felt desirable for a patient to be maintained on a specific manufacturer&#8217;s product, this should be prescribed either by specifying a brand name, or by using the generic drug name and name of the manufacturer (otherwise known as the Marketing Authorisation Holder)</li>\n\n<li>Please report on a Yellow Card any suspected adverse reactions to AEDs (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n\n<li>This advice relates only to AED use for treatment of epilepsy; it does not apply to their use in other indications (eg, mood stabilisation, neuropathic pain)</li>\n</ul>\n\n<p><strong>Additional advice for pharmacists:</strong></p>\n\n<ul>\n<li>Dispensing pharmacists should ensure the continuity of supply of a particular product when the prescription specifies it. If the prescribed product is unavailable, it may be necessary to dispense a product from a different manufacturer to maintain continuity of treatment of that AED. Such cases should be discussed and agreed with both the prescriber and patient (or carer)</li>\n\n<li>Usual dispensing practice can be followed when a specific product is not stated</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON336730\">Information sheet for patients or carers</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antiepilepticschangingproducts/index.htm\">MHRA website information</a> on prescribing and dispensing of antiepileptic drugs</p>\n\n<p>See also letter sent via the <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102066\">Central Alerting System, Nov 11, 2013</a></p>\n\n<em>Article citation: Drug Safety Update date volume 7 issue 4, November 2013: A1.</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Bioequivalence and antiepileptic drugs</strong></p>\n\n<p>When a generic medicinal product is shown to be bioequivalent to the originator (reference) product, as defined by the relevant regulations and guidelines, it follows that the products can be considered to be clinically equivalent. However, concerns about switching between different manufacturers&#8217; products of an oral antiepileptic drug (AED) have been raised by patients and prescribers. These include switching between branded originator and generic products, and between different generic products of a particular drug. The main reasons for these concerns are the narrow therapeutic index of some AEDs and the potentially serious consequences of therapeutic failure. Drug&#8211;drug interactions and the relatively low solubility or bioavailability (or both) of some AEDs are other important factors.</p>\n\n<p><strong>Potential risk from switching between different manufacturers&#8217; products</strong></p>\n\n<p>The Commission on Human Medicines (CHM) reviewed spontaneous adverse reactions received by MHRA and publications that reported potential harm arising from switching of AEDs in patients previously stabilised on a branded product to a generic. Following this review, CHM concluded that reports of loss of seizure control and/or worsening of side effects around the time of switching between products could be explained as chance associations, but that a causal role of switching could not be ruled out in all cases.</p>\n\n<p><strong>New categorisation to help minimise risk</strong></p>\n\n<p>The CHM considered the characteristics of AEDs and advised that they could be classified into three categories based on therapeutic index, solubility, and absorption to help prescribers and patients decide whether it was necessary to maintain continuity of supply of a specific manufacturer&#8217;s product. These categories are listed below:</p>\n\n<div class=\"websitebluehighlightbox70\">\n<ul>\n<li><strong>Category 1 &#8211; </strong>phenytoin, carbamazepine, phenobarbital, primidone</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer&#8217;s product</p>\n</li>\n\n<li><strong>Category 2 &#8211; </strong>valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, the need for continued supply of a particular manufacturer&#8217;s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history</p>\n</li>\n\n<li><strong>Category 3 - </strong>levetiracetam, lacosamide, tiagabine, gabapentin, pregabalin, ethosuximide, vigabatrin<strong> </strong>&#160;</li>\n\n<li style=\" list-style: none;\">\n<p>For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer&#8217;s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors</p>\n</li>\n</ul>\n</div>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for prescribers:</strong></p>\n\n<ul>\n<li>Different AEDs vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers&#8217; products of a particular drug may cause adverse effects or loss of seizure control</li>\n\n<li>AEDs have been divided into three categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer&#8217;s product</li>\n\n<li>If it is felt desirable for a patient to be maintained on a specific manufacturer&#8217;s product, this should be prescribed either by specifying a brand name, or by using the generic drug name and name of the manufacturer (otherwise known as the Marketing Authorisation Holder)</li>\n\n<li>Please report on a Yellow Card any suspected adverse reactions to AEDs (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n\n<li>This advice relates only to AED use for treatment of epilepsy; it does not apply to their use in other indications (eg, mood stabilisation, neuropathic pain)</li>\n</ul>\n\n<p><strong>Additional advice for pharmacists:</strong></p>\n\n<ul>\n<li>Dispensing pharmacists should ensure the continuity of supply of a particular product when the prescription specifies it. If the prescribed product is unavailable, it may be necessary to dispense a product from a different manufacturer to maintain continuity of treatment of that AED. Such cases should be discussed and agreed with both the prescriber and patient (or carer)</li>\n\n<li>Usual dispensing practice can be followed when a specific product is not stated</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con336730.pdf\" target='new\"\"'>Information sheet for patients or carers<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (361Kb)</p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antiepilepticschangingproducts/index.htm\">MHRA website information</a> on prescribing and dispensing of antiepileptic drugs</p>\n\n<p>See also letter sent via the <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102066\">Central Alerting System, Nov 11, 2013</a></p>\n\n<em>Article citation: Drug Safety Update date volume 7 issue 4, November 2013: A1.</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-11-01", 
  "date_last_modified": "2013-11-18", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Information sheet for patients or carers", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con336730.pdf", 
      "filename": "downloads/2c315d7f8293eb31fa07736aabda1212a3aa914f/con336730.pdf", 
      "original_filename": "con336730.pdf"
    }
  ], 
  "_item_id": 52, 
  "summary": "Different antiepileptic drugs (AEDs) vary considerably in their characteristics, which influences the risk of whether switching between different manufacturersâ€™ products of a particular drug may cause adverse effects or loss of seizure control. AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturerâ€™s product", 
  "body": "Article date: November 2013\n\nBioequivalence and antiepileptic drugs\n\nWhen a generic medicinal product is shown to be bioequivalent to the originator (reference) product, as defined by the relevant regulations and guidelines, it follows that the products can be considered to be clinically equivalent. However, concerns about switching between different manufacturersâ€™ products of an oral antiepileptic drug (AED) have been raised by patients and prescribers. These include switching between branded originator and generic products, and between different generic products of a particular drug. The main reasons for these concerns are the narrow therapeutic index of some AEDs and the potentially serious consequences of therapeutic failure. Drugâ€“drug interactions and the relatively low solubility or bioavailability (or both) of some AEDs are other important factors.\n\nPotential risk from switching between different manufacturersâ€™ products\n\nThe Commission on Human Medicines (CHM) reviewed spontaneous adverse reactions received by MHRA and publications that reported potential harm arising from switching of AEDs in patients previously stabilised on a branded product to a generic. Following this review, CHM concluded that reports of loss of seizure control and/or worsening of side effects around the time of switching between products could be explained as chance associations, but that a causal role of switching could not be ruled out in all cases.\n\nNew categorisation to help minimise risk\n\nThe CHM considered the characteristics of AEDs and advised that they could be classified into three categories based on therapeutic index, solubility, and absorption to help prescribers and patients decide whether it was necessary to maintain continuity of supply of a specific manufacturerâ€™s product. These categories are listed below:  \n  \n  * Category 1 â€“ phenytoin, carbamazepine, phenobarbital, primidone  \n  * For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturerâ€™s product  \n  \n  * Category 2 â€“ valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate  \n  * For these drugs, the need for continued supply of a particular manufacturerâ€™s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history  \n  \n  * Category 3 - levetiracetam, lacosamide, tiagabine, gabapentin, pregabalin, ethosuximide, vigabatrin Â   \n  * For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturerâ€™s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors  \n  \nAdvice for prescribers:  \n  \n  * Different AEDs vary considerably in their characteristics, which influences the risk of whether switching between different manufacturersâ€™ products of a particular drug may cause adverse effects or loss of seizure control  \n  * AEDs have been divided into three categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturerâ€™s product  \n  * If it is felt desirable for a patient to be maintained on a specific manufacturerâ€™s product, this should be prescribed either by specifying a brand name, or by using the generic drug name and name of the manufacturer (otherwise known as the Marketing Authorisation Holder)  \n  * Please report on a Yellow Card any suspected adverse reactions to AEDs ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard))  \n  * This advice relates only to AED use for treatment of epilepsy; it does not apply to their use in other indications (eg, mood stabilisation, neuropathic pain)  \n  \nAdditional advice for pharmacists:  \n  \n  * Dispensing pharmacists should ensure the continuity of supply of a particular product when the prescription specifies it. If the prescribed product is unavailable, it may be necessary to dispense a product from a different manufacturer to maintain continuity of treatment of that AED. Such cases should be discussed and agreed with both the prescriber and patient (or carer)  \n  * Usual dispensing practice can be followed when a specific product is not stated  \n  \nFurther information:\n\n[ASSET_TAG](#ASSET0) (361Kb)\n\n[MHRA website information](http://www.mhra.gov.uk/safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antiepilepticschangingproducts/index.htm) on prescribing and dispensing of antiepileptic drugs\n\nSee also letter sent via the [Central Alerting System, Nov 11, 2013](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102066)\n\nArticle citation: Drug Safety Update date volume 7 issue 4, November 2013: A1.\n"
}